Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Belantamab mafodotin for myeloma: Phase 1 data & patient-reported outcomes

Rakesh Popat • 14 Jun 2019
EHA 2019
Multiple Myeloma Belantamab mafodotin
DREAMM-1

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the data on the BCMA-directed antibody-drug conjugate belantamab mafodotin (GSK2857916) from the first-in-human Phase I trial (DREAMM-1; NCT02064387) and patient-reported outcomes. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Rakesh Popat

2:06
The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat • 16 Feb 2024
3:46
'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat • 16 Feb 2024
1:30
Selecting patients with myeloma for CAR-T: important clinical considerations
Rakesh Popat • 16 Feb 2024
1:14
The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat • 10 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals